ILAPRAZOLE: A SUPERIOR PROTON PUMP INHIBITOR FOR
PEPTIC ULCER DISEASE?
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: DHANARAJU, Magharla (GIET School Of Pharmacy, Pharmaceutical Sciences, Rajahmundry, India)
- Co-author(s): Magharla Dasaratha Dhanaraju
Epidemiology of peptic ulcer disease (PUD) in India differs from that in the West. We therefore tried to assess the efficiency of the recently approved proton pump inhibitor with the proven Rabeprazole.
The study was a prospective, randomized open label comparison, total of 141 in which 70 patients received 10mg Ilaprazole and 71 patients received.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.